阿拉斯加原住民9-14岁儿童接种四价人乳头瘤病毒疫苗后5年的免疫原性
2011-2014年纳入469名9-14岁阿拉斯加原住民儿童,接种3剂四价HPV疫苗,于接种后1个月及1、2、3、5年采集血清。所有受试者在各时间点对4种HPV型别均可检出抗体,抗体水平1个月达峰后逐渐下降;接种后5年,接种时年龄较小的儿童抗体水平更高。
要点
- 所有469名儿童在接种后各时间点对HPV 6/11/16/18型均可检出抗体。
- 4种型别抗体水平均在接种后1个月达峰,随后逐年下降。
- 接种后5年,接种时年龄较小的儿童抗体水平更高。
核心结论
- 阿拉斯加原住民儿童在接种四价HPV疫苗后5年仍维持针对全部4种疫苗型别的抗体。
研究设计与样本
- 2011-2014年纳入469名9-14岁阿拉斯加原住民儿童,接种3剂四价HPV疫苗,于接种后1个月及1、2、3、5年采集血清,评估型特异性IgG抗体浓度趋势。
主要发现
- 全部469名受试者在接种后各时间点对HPV 6/11/16/18型均可检出抗体。
- 4种型别抗体水平均在接种后1个月达峰,随后逐年逐渐下降。
- 接种后5年,接种时年龄较小的儿童抗体水平更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persistent human papillomavirus (HPV) infection can cause anogenital and oropharyngeal cancers. Many HPV infections and HPV-associated cancers are vaccine-preventable. Studies suggest long-term persistence of vaccine-induced antibodies. However, data are limited among Alaska Native people. METHODS: During 2011-2014, we enrolled Alaska Native children aged 9-14 years who received a 3-dose series of quadrivalent HPV vaccine (4vHPV). We collected sera at 1 month and 1, 2, 3, and 5 years post-vaccination to evaluate trends in type-specific immunoglobulin G antibody concentrations for the 4vHPV types (HPV 6/11/16/18). RESULTS: All participants (N = 469) had detectable antibodies against all 4vHPV types at all timepoints post-vaccination. For all 4vHPV types, antibody levels peaked by 1 month post-vaccination and gradually declined in subsequent years. At 5 years post-vaccination, antibody levels were higher among children who received 4vHPV at a younger age. CONCLUSIONS: Alaska Native children maintained antibodies against all 4vHPV types at 5 years post-vaccination.
引用
- Davis BM, Blake I, Panicker G, et al. Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination. Vaccine. 2024. PMID: 38627144. doi:10.1016/j.vaccine.2024.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。